Curaleaf to acquire EMMAC Life Sciences for $286m.

Curaleaf, a US provider of consumer products in cannabis, agreed to acquire EMMAC Life Sciences, the vertically integrated independent cannabis company in Europe, for $286m. "The consumer and political liberalization trends around cannabis that are sweeping the US are also increasingly taking hold in Europe. Curaleaf will seek to leverage our branded cannabis consumer packaged goods strategy across Europe, a market which provides for cross-border cannabis distribution. The European cannabis market has the potential to exceed the US cannabis market over the long-term and will help fuel our growth for years to come," Boris Jordan, Curaleaf Executive Chairman.